Optimizing Access to Unrelated Donors in Canada: Re-Examining the Importance of Donor Factors on Outcomes Following Hematopoietic Cell Transplantation.

Gaganvir Parmar, Matthew D Seftel, Kathy Ganz, John Blake, Jelena L Holovati, David S Allan

Abstract readReview

In one paragraph

Review in Current oncology (Toronto, Ont.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

The transformative impact of ultra-rapid nanopore sequencing in precision medicine.Frontiers in immunology · 2026
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Gaganvir ParmarStem Cells, Canadian Blood Services, Ottawa, ON K1Z 7M3, Canada.

Matthew D SeftelStem Cells, Canadian Blood Services, Ottawa, ON K1Z 7M3, Canada.ORCID 0000-0002-0960-2687

Kathy GanzStem Cells, Canadian Blood Services, Ottawa, ON K1Z 7M3, Canada.

John BlakeStem Cells, Canadian Blood Services, Ottawa, ON K1Z 7M3, Canada.ORCID 0000-0003-0617-8996

Jelena L HolovatiStem Cells, Canadian Blood Services, Ottawa, ON K1Z 7M3, Canada.

David S AllanStem Cells, Canadian Blood Services, Ottawa, ON K1Z 7M3, Canada.ORCID 0000-0003-3261-8289

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

HLA-matched allogeneic hematopoietic cell transplantation (HCT) is a curative therapy for many patients. Unrelated HLA-matched donors are the most frequently used donor for HCT. When more than one donor transplant option is available, transplant centers can select donors based on non-HLA factors. With improved ability to prevent and treat immune complications, such as graft-versus-host disease and infections, it may be possible to proceed more often using HLA-mismatched donors, allowing greater consideration of non-HLA factors, such as donor age, CMV serostatus, and ABO blood group matching, which have demonstrated important impacts on transplant outcomes. Additional factors to consider are donor availability rates and the usage of domestic donors to optimize outcomes. A review of non-HLA factors and considerations on the selection of optimal unrelated donors for HCT are provided within this updated current context.

Indexed as

Hematopoietic Stem Cell TransplantationUnrelated DonorsCanadaHumansTreatment Outcomeallogeneicdonorhematopoietic cell transplantationoutcomesregistryselection

Identifiers

PMID38785471

DOI10.3390/curroncol31050190

PMCPMC11119328

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.